Charles Jobson Buys 5,240 Shares of Joint (NASDAQ:JYNT) Stock

The Joint Corp. (NASDAQ:JYNT) major shareholder Charles Jobson purchased 5,240 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were purchased at an average cost of $8.89 per share, with a total value of $46,583.60. Following the purchase, the insider owned 1,621,671 shares of the company’s stock, valued at approximately $14,416,655.19. The trade was a 0.32% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Joint Trading Up 2.9%

Shares of Joint stock opened at $9.24 on Friday. The firm has a market capitalization of $137.40 million, a PE ratio of -153.97 and a beta of 1.29. The Joint Corp. has a 12 month low of $7.50 and a 12 month high of $13.47. The business’s 50-day moving average price is $8.56 and its 200-day moving average price is $9.70.

Joint (NASDAQ:JYNT) last released its earnings results on Friday, November 7th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The company had revenue of $13.38 million during the quarter, compared to the consensus estimate of $13.36 million. Joint had a negative return on equity of 0.98% and a negative net margin of 1.78%. As a group, analysts predict that The Joint Corp. will post 0.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. B. Riley lowered shares of Joint from a “buy” rating to a “hold” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Joint in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Joint has an average rating of “Hold” and an average price target of $17.00.

Institutional Investors Weigh In On Joint

Institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its stake in shares of Joint by 5,141.9% during the second quarter. Nisa Investment Advisors LLC now owns 2,254 shares of the company’s stock valued at $26,000 after acquiring an additional 2,211 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Joint by 104.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company’s stock worth $28,000 after buying an additional 1,501 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Joint by 32.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock worth $86,000 after buying an additional 1,810 shares during the last quarter. MetLife Investment Management LLC purchased a new position in shares of Joint during the first quarter valued at approximately $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Joint by 25.9% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock worth $95,000 after acquiring an additional 1,698 shares during the period. Hedge funds and other institutional investors own 76.88% of the company’s stock.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.